Inspection prep notes · Laboratory
OOS investigations
Also called: OOS, out-of-specification, out of specification
FDA looks less at whether an OOS result occurred than at whether it was investigated on scientific grounds to find the cause, and whether it was replaced by a passing result without justification. The findings below are quoted from warning letters and FDA 483s.
What inspectors cited
1The investigation did not determine the root cause
The laboratory OOS investigations did not identify potential root causes for the initial OOS result and no justifications were provided for the high (~6%) testing variabilities observed during the retesting by the [redacted].
FDA 483 · Frontage Laboratories, Inc. · 2026-10-23 · View document
You failed to determine the root cause of the out-of-specification (OOS) and implement the appropriate CAPA.
FDA Warning Letter · Vegewax Candleworx Ltd. · 2025-03-18
2The original result was invalidated without scientific justification
You invalidated the sterility result without adequate scientific justification and released this lot in July 2025.
FDA Warning Letter · Baxter International Inc. · 2026-10-20 · View document
The firm invalidated the original result based on passing result from the single new sample and new standard (second).
FDA 483 · Sumitomo Osaka Cement Co., Ltd · 2026-11-05 · View document
3Batches were released on retest results without judging the validity of the original test
Your test method procedures allowed multiple retesting of samples following an OOS result, often until an acceptable result is obtained.
FDA Warning Letter · SnugZ USA, Inc. · 2026-10-20 · View document
Both BCG batches, [redacted] and [redacted], were subsequently released based on the retest results without properly determining the validity of the original test.
FDA 483 · Merck Teknika LLC · 2026-10-27 · View document
4The investigation was not extended to other batches that may have been affected
Although you rejected the batch, you failed to adequately assess the root cause of the microbiological contamination, and you failed to extend the investigation to additional batches that may also have been affected.
FDA Warning Letter · Absolutely Natural · 2026-01-06 · View document
Additionally, the investigation scope was not broadened to consider potential impact to other batches manufactured by the same process.
FDA 483 · PQ Pharmacy LLC · 2026-09-22 · View document
5The investigation was not opened, or was opened late
Your contract testing laboratory reported an OOS result for (b)(4) on August 28, 2024, but you did not initiate the Phase II investigation until December 4, 2024.
FDA Warning Letter · VeganicSKN Limited · 2026-09-29 · View document
A review of raw data from in-process testing revealed that several batches had failed in-process test results. No manufacturing deviations or documentation in the executed batch records were available for these failures.
FDA 483 · Alkem Laboratories Limited · 2026-07-27 · View document
Questions to check against your procedures
- Does each OOS investigation report state the root cause and the evidence for it? Where no cause was found, how was the CAPA decided?
- Is there documented scientific justification for each invalidated original result? Was any result invalidated only on a passing result from a new sample or a new standard?
- Do test procedures allow retesting without an investigation? Is the number of retests defined?
- For batches released on retest results, was the validity of the original test judged first and approved by the quality unit?
- When an OOS occurs, is the investigation extended to other batches made by the same process?
- Are there cases with a gap between the date the OOS was reported and the date the investigation was opened? Are in-process test failures recorded as deviations too?
Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-15.